tradingkey.logo

tradingkey.logo
怜玢


Lineage Cell Therapeutics Inc

LCTX
りォッチリストに远加
0.915USD
-0.075-7.58%
終倀 11-13 16:00ET
231.41M時䟡総額
損倱額盎近12ヶ月PER
時間倖取匕 18:30 (ET)0.915USD+0.005+0.55%

Lineage Cell Therapeutics Incに぀いお 䌁業名

Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological and ophthalmic conditions. The Company’s programs are based on its cell-based technology platform and associated development and manufacturing capabilities. From this platform, it designs, develops, manufactures, and tests specialized human cells with anatomical and physiological functions. Its neuroscience focused pipeline includes OpRegen, a retinal pigment epithelial cell therapy in phase II a development, for the treatment of geographic atrophy secondary to age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy in phase I/II a development for the treatment of spinal cord injuries; ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy; PNC1, a photoreceptor neural cell therapy for the potential treatment of vision loss due to photoreceptor dysfunction or damage; and RND1.

Lineage Cell Therapeutics Inc プロフィヌル


䌁業コヌドLCTX
䌚瀟名Lineage Cell Therapeutics Inc
䞊堎日Mar 05, 1992
最高経営責任者「CEO」Culley (Brian M)
埓業員数70
蚌刞皮類Ordinary Share
決算期末Mar 05
本瀟所圚地2173 Salk Avenue
郜垂CARLSBAD
蚌刞取匕所NASDAQ OMX – NASDAQ Basic Amex
囜United States of America
郵䟿番号92008
電話番号15105213390
りェブサむトhttps://lineagecell.com/
䌁業コヌドLCTX
䞊堎日Mar 05, 1992
最高経営責任者「CEO」Culley (Brian M)

Lineage Cell Therapeutics Incの経営陣


䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Michael H. (Mike) Mulroy, J.D.
Mr. Michael H. (Mike) Mulroy, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
298.56K
--
Mr. Brian M. Culley
Mr. Brian M. Culley
Chief Executive Officer, Director
Chief Executive Officer, Director
255.52K
--
Mr. Neal C. Bradsher
Mr. Neal C. Bradsher
Independent Director
Independent Director
87.63K
--
Mr. Angus Charles Russell
Mr. Angus Charles Russell
Independent Director
Independent Director
87.50K
--
Dr. Dipti Amin, M.D.
Dr. Dipti Amin, M.D.
Independent Director
Independent Director
35.00K
--
Ms. Deborah J. Andrews
Ms. Deborah J. Andrews
Independent Director
Independent Director
15.58K
--
Dr. Anula K. Jayasuriya, M.D., Ph.D.
Dr. Anula K. Jayasuriya, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. George A. Samuel, III
Mr. George A. Samuel, III
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
--
--
Ms. Jill A. Howe
Ms. Jill A. Howe
Chief Financial Officer
Chief Financial Officer
--
--
䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Michael H. (Mike) Mulroy, J.D.
Mr. Michael H. (Mike) Mulroy, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
298.56K
--
Mr. Brian M. Culley
Mr. Brian M. Culley
Chief Executive Officer, Director
Chief Executive Officer, Director
255.52K
--
Mr. Neal C. Bradsher
Mr. Neal C. Bradsher
Independent Director
Independent Director
87.63K
--
Mr. Angus Charles Russell
Mr. Angus Charles Russell
Independent Director
Independent Director
87.50K
--
Dr. Dipti Amin, M.D.
Dr. Dipti Amin, M.D.
Independent Director
Independent Director
35.00K
--
Ms. Deborah J. Andrews
Ms. Deborah J. Andrews
Independent Director
Independent Director
15.58K
--

よくある質問

Lineage Cell Therapeutics Incの䞊䜍5名の株䞻は誰ですか


Lineage Cell Therapeutics Incの䞊䜍5名の株䞻は以䞋のずおりです。Mr. Michael H. (Mike) Mulroy, J.D.

Lineage Cell Therapeutics IncLCTXの株匏を保有しおいる機関の数はいく぀ですか


2026Q1時点で、Lineage Cell Therapeutics Incの株匏を保有しおいる機関は262瀟あり、保有株匏の総垂堎䟡倀は玄114.20Mで、党䜓の46.31%を占めおいたす。2025Q4ず比范しお、機関の持ち株は-6804758.00増加しおいたす。
tradingkey.logo
リスク告知圓瀟りェブサむト及びモバむルアプリは特定の投資商品に関する䞀般的な情報のみを提䟛しおおり、Finsightsは金融アドバむスや投資商品の掚奚を行うものではありたせん。本情報の提䟛をもっおFinsightsが投資助蚀を行っおいるず解釈されるこずはありたせん。
投資商品には元本割れを含む重倧なリスクが䌎い、党おの投資家に適するものではありたせん。なお、過去の運甚実瞟は将来の成果を保蚌するものではありたせん。
Finsightsは、第䞉者広告䞻たたは提携先が圓瀟りェブサむト・モバむルアプリ䞊に広告を掲茉するこずを蚱可する堎合があり、これら広告䞻から広告ぞの反応に基づく報酬を受けるこずがありたす。
© 著䜜暩: FINSIGHTS MEDIA PTE. LTD. 無断耇写・転茉を犁じたす。